Cyp2c39 Inhibitors
Cyp2c39 inhibitors are a specialized class of chemical compounds designed to specifically target and inhibit the activity of the Cyp2c39 enzyme, a member of the cytochrome P450 superfamily. Cyp2c39 plays a pivotal role in the oxidative metabolism of a broad spectrum of substrates, which includes endogenous molecules such as lipids, hormones, and various signaling molecules, as well as exogenous compounds like pharmaceuticals and environmental toxins. The enzyme functions by catalyzing the monooxygenation of these substrates, a biochemical reaction that incorporates an oxygen atom into the substrate molecule. This oxidation process typically enhances the solubility of the substrates, facilitating their further metabolism, conjugation, or excretion from the body. Cyp2c39, like other cytochrome P450 enzymes, is primarily active in the liver, where it contributes significantly to the detoxification and metabolic processes essential for maintaining physiological balance.
Inhibitors of Cyp2c39 are generally small molecules that interact directly with the enzyme's active site, blocking its ability to bind and metabolize its substrates. These inhibitors function by occupying the enzyme's substrate-binding pocket, thereby preventing the access of natural substrates to the catalytic site, or by inducing conformational changes that reduce the enzyme's catalytic efficiency. The development of Cyp2c39 inhibitors involves a thorough understanding of the enzyme's three-dimensional structure, particularly the regions critical for substrate recognition and catalysis. By inhibiting Cyp2c39, researchers can delve into the enzyme's specific role in various metabolic pathways, investigating how the inhibition of Cyp2c39 impacts the broader network of cytochrome P450-mediated reactions. The study of Cyp2c39 inhibitors is crucial for understanding the enzyme's substrate specificity, its interaction with other metabolic enzymes, and its overall contribution to the metabolic processes that sustain cellular and systemic homeostasis. This research advances our knowledge of the intricate roles that cytochrome P450 enzymes play in the metabolism of both endogenous and exogenous compounds within biological systems.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Fluconazole | 86386-73-4 | sc-205698 sc-205698A | 500 mg 1 g | $54.00 $84.00 | 14 | |
Fluconazole serves as a direct inhibitor of Cyp2c39, disrupting arachidonic acid 11,12-epoxygenase and 14,15-epoxygenase activities. It interferes with the arachidonic acid metabolic process, influencing cellular responses related to diseases such as Plasmodium falciparum malaria and eosinophilic esophagitis. | ||||||
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $63.00 $265.00 | 21 | |
Ketoconazole inhibits Cyp2c39 directly, disrupting arachidonic acid 11,12-epoxygenase and 14,15-epoxygenase activities. It modulates cellular responses related to arachidonic acid metabolism, potentially affecting diseases such as multiple chemical sensitivity. | ||||||
Abiraterone | 154229-19-3 | sc-460288 | 10 mg | $276.00 | ||
Abiraterone serves as a direct inhibitor of Cyp2c39, influencing arachidonic acid 11,12-epoxygenase and 14,15-epoxygenase activities. It impacts cellular responses linked to diseases, including Plasmodium falciparum malaria and eosinophilic esophagitis. | ||||||
Fluoxetine | 54910-89-3 | sc-279166 | 500 mg | $318.00 | 9 | |
Fluoxetine acts as a direct inhibitor of Cyp2c39, disrupting arachidonic acid metabolism. By affecting epoxygenase activities, it modulates pathways associated with diseases like invasive aspergillosis and multiple chemical sensitivity. | ||||||
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
Cimetidine inhibits Cyp2c39 directly, disrupting arachidonic acid 11,12-epoxygenase and 14,15-epoxygenase activities. It influences cellular responses related to diseases such as glucose metabolism disease and invasive aspergillosis. | ||||||
Miconazole | 22916-47-8 | sc-204806 sc-204806A | 1 g 5 g | $66.00 $160.00 | 2 | |
Miconazole serves as a direct inhibitor of Cyp2c39, impacting arachidonic acid 11,12-epoxygenase and 14,15-epoxygenase activities. It modulates cellular responses linked to diseases, including Plasmodium falciparum malaria and eosinophilic esophagitis. | ||||||
Fluvoxamine | 54739-18-3 | sc-207697 | 25 mg | $321.00 | 1 | |
Fluvoxamine acts as a direct inhibitor of Cyp2c39, disrupting arachidonic acid metabolism. By affecting epoxygenase activities, it modulates pathways associated with diseases like invasive aspergillosis and multiple chemical sensitivity. | ||||||
Clotrimazole | 23593-75-1 | sc-3583 sc-3583A | 100 mg 1 g | $42.00 $57.00 | 6 | |
Clotrimazole inhibits Cyp2c39 directly, disrupting arachidonic acid 11,12-epoxygenase and 14,15-epoxygenase activities. It influences cellular responses related to diseases such as glucose metabolism disease and invasive aspergillosis. | ||||||
Itraconazole | 84625-61-6 | sc-205724 sc-205724A | 50 mg 100 mg | $78.00 $142.00 | 23 | |
Itraconazole serves as a direct inhibitor of Cyp2c39, impacting arachidonic acid 11,12-epoxygenase and 14,15-epoxygenase activities. It modulates cellular responses linked to diseases, including Plasmodium falciparum malaria and eosinophilic esophagitis. | ||||||